← All trials
NCT03388385
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 20, 2017
- Primary completion
- Sep 20, 2018
- Completion date
- Oct 30, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 40
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Carol Davila University of Medicine and PharmacyLead sponsor
- Carol Davila University of Medicine and PharmacyReponsible party - principal investigator
- Carol Davila University of Medicine and PharmacyStudy chair
- Carol Davila University of Medicine and PharmacyStudy director
- S.C. Sanador S.R.LCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.